These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37595251)

  • 1. HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.
    Li L; Tianrui K; Chunlei L; Zhendong Q; Xiaoyan C; Wenhong D
    Aging (Albany NY); 2023 Aug; 15(16):7997-8012. PubMed ID: 37595251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer.
    Zhou Y; Tan Y; Zhang Q; Duan Q; Chen J
    Eur J Med Res; 2022 Oct; 27(1):225. PubMed ID: 36309740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
    Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
    J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
    Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z
    Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.
    Jiang Y; Hu X; Wang Z; Zhang Q; Chen D; Zhao P
    Invest New Drugs; 2024 Feb; 42(1):60-69. PubMed ID: 38071684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.
    Fu C; Gu H; Sun L; Wang Z; Zhang Q; Luo N; Chen D; Zhou T
    Invest New Drugs; 2024 Oct; ():. PubMed ID: 39369144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Li Y; Yang Q; Liu Y; Yi H; Ju Y; Qi G
    Invest New Drugs; 2023 Aug; 41(4):556-563. PubMed ID: 37318657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
    Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
    Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer.
    Deng S; Gu H; Chen Z; Liu Y; Zhang Q; Chen D; Yi S
    Carcinogenesis; 2024 May; 45(5):351-357. PubMed ID: 38310539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts.
    Long JY; Li RZ; Wang DX; Liu H; Tian J; Ding ZN; Yan LJ; Dong ZR; Hong JG; Tian BW; Han CL; Zhao HT; Li T
    Int Immunopharmacol; 2024 Jan; 126():111281. PubMed ID: 38061115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment.
    Deng C; Li ZX; Xie CJ; Zhang QL; Hu BS; Wang MD; Mei J; Yang C; Zhong Z; Wang KW
    Hum Genomics; 2024 May; 18(1):55. PubMed ID: 38822443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
    Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C
    Front Immunol; 2022; 13():894110. PubMed ID: 35967450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma.
    Pan C; Tang H; Wang W; Wu D; Luo H; Xu L; Lin XJ
    Front Oncol; 2022; 12():1077477. PubMed ID: 36733353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis.
    Cao J; Yang X; Chen S; Wang J; Fan X; Fu S; Yang L
    Transl Oncol; 2022 Jun; 20():101375. PubMed ID: 35339028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.